Timothy Rolph, Chief Scientific Officer at Akero Therapeutics, Inc. (AKRO), sold 9,636 shares at $30.79 ($298K) on 2024-12-10, disclosed to the SEC on 2024-12-12.
Scheduled sale ($298k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $30.79 | 2,368 | $73K | 24.5% |
| 2 | $30.79 | 2,368 | $73K | 24.5% |
| 3 | $31.03 | 2,450 | $76K | 25.5% |
| 4 | $31.03 | 2,450 | $76K | 25.5% |
| Total | $30.91 avg | 9,636 | $298K | 100% |
| Filing → |
| AKRO | SELL | 2025-09-10 | $1.1M | — | Filing → |
| AKRO | SELL | 2025-08-07 | $1.2M | — | Filing → |
| AKRO | SELL | 2025-07-09 | $1.2M | — | Filing → |